FDA pharmacologic class
Interleukin-13 Antagonist
2 medicines are in FDA's class of interleukin-13 antagonists: lebrikizumab (Ebglyss) and tralokinumab (Adbry). 0 of the 2 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is ebglyss 250 mg/2 ml pen at $1,783.52 per mL (NADAC).
Which medicines are interleukin-13 antagonist?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Lebrikizumab | Ebglyss | none listed | $1,783.52 per mL 250 mg/2 mL pen | No | No current entry | 0 |
| Tralokinumab | Adbry | none listed | n/a | No | No current entry | 1 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price